

# Metabolic Disorders Therapeutics-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

<https://marketpublishers.com/r/ME85C681305EN.html>

Date: January 2018

Pages: 138

Price: US\$ 3,680.00 (Single User License)

ID: ME85C681305EN

## Abstracts

### Report Summary

Metabolic Disorders Therapeutics-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Metabolic Disorders Therapeutics industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Metabolic Disorders Therapeutics 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Metabolic Disorders Therapeutics worldwide and market share by regions, with company and product introduction, position in the Metabolic Disorders Therapeutics market

Market status and development trend of Metabolic Disorders Therapeutics by types and applications

Cost and profit status of Metabolic Disorders Therapeutics, and marketing status

Market growth drivers and challenges

The report segments the global Metabolic Disorders Therapeutics market as:

Global Metabolic Disorders Therapeutics Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)  
Asia Pacific (China, Japan, India, Southeast Asia and Australia)  
Latin America (Brazil, Argentina and Colombia)  
Middle East and Africa

Global Metabolic Disorders Therapeutics Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Metachromatic Leukodystrophy  
Globoid Leukodystrophy  
Hepatic Encephalopathy  
Others

Global Metabolic Disorders Therapeutics Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Diabetes  
Obesity  
Hypercholesterolemia  
Lysosomal storage diseases

Global Metabolic Disorders Therapeutics Market: Manufacturers Segment Analysis (Company and Product introduction, Metabolic Disorders Therapeutics Sales Volume, Revenue, Price and Gross Margin):

Novo Nordisk  
Sanofi  
Merck  
AstraZeneca  
Eli Lilly  
AbbVie  
Actelion Pharmaceuticals  
Adocia  
Aegerion Pharmaceuticals  
Akros Pharma  
Alnylam Pharmaceuticals  
Amarin  
Amicus Therapeutics

Biopharma  
Arena Pharmaceuticals  
Astellas Pharma  
Bionaturis  
Diasome Pharmaceuticals  
Lexicon Pharmaceuticals  
Ligand Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF METABOLIC DISORDERS THERAPEUTICS**

- 1.1 Definition of Metabolic Disorders Therapeutics in This Report
- 1.2 Commercial Types of Metabolic Disorders Therapeutics
  - 1.2.1 Metachromatic Leukodystrophy
  - 1.2.2 Globoid Leukodystrophy
  - 1.2.3 Hepatic Encephalopathy
  - 1.2.4 Others
- 1.3 Downstream Application of Metabolic Disorders Therapeutics
  - 1.3.1 Diabetes
  - 1.3.2 Obesity
  - 1.3.3 Hypercholesterolemia
  - 1.3.4 Lysosomal storage diseases
- 1.4 Development History of Metabolic Disorders Therapeutics
- 1.5 Market Status and Trend of Metabolic Disorders Therapeutics 2013-2023
  - 1.5.1 Global Metabolic Disorders Therapeutics Market Status and Trend 2013-2023
  - 1.5.2 Regional Metabolic Disorders Therapeutics Market Status and Trend 2013-2023

### **CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Development of Metabolic Disorders Therapeutics 2013-2017
- 2.2 Sales Market of Metabolic Disorders Therapeutics by Regions
  - 2.2.1 Sales Volume of Metabolic Disorders Therapeutics by Regions
  - 2.2.2 Sales Value of Metabolic Disorders Therapeutics by Regions
- 2.3 Production Market of Metabolic Disorders Therapeutics by Regions
- 2.4 Global Market Forecast of Metabolic Disorders Therapeutics 2018-2023
  - 2.4.1 Global Market Forecast of Metabolic Disorders Therapeutics 2018-2023
  - 2.4.2 Market Forecast of Metabolic Disorders Therapeutics by Regions 2018-2023

### **CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Sales Volume of Metabolic Disorders Therapeutics by Types
- 3.2 Sales Value of Metabolic Disorders Therapeutics by Types
- 3.3 Market Forecast of Metabolic Disorders Therapeutics by Types

### **CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Global Sales Volume of Metabolic Disorders Therapeutics by Downstream Industry
- 4.2 Global Market Forecast of Metabolic Disorders Therapeutics by Downstream Industry

## **CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 5.1 North America Metabolic Disorders Therapeutics Market Status by Countries
  - 5.1.1 North America Metabolic Disorders Therapeutics Sales by Countries (2013-2017)
  - 5.1.2 North America Metabolic Disorders Therapeutics Revenue by Countries (2013-2017)
  - 5.1.3 United States Metabolic Disorders Therapeutics Market Status (2013-2017)
  - 5.1.4 Canada Metabolic Disorders Therapeutics Market Status (2013-2017)
  - 5.1.5 Mexico Metabolic Disorders Therapeutics Market Status (2013-2017)
- 5.2 North America Metabolic Disorders Therapeutics Market Status by Manufacturers
- 5.3 North America Metabolic Disorders Therapeutics Market Status by Type (2013-2017)
  - 5.3.1 North America Metabolic Disorders Therapeutics Sales by Type (2013-2017)
  - 5.3.2 North America Metabolic Disorders Therapeutics Revenue by Type (2013-2017)
- 5.4 North America Metabolic Disorders Therapeutics Market Status by Downstream Industry (2013-2017)

## **CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 6.1 Europe Metabolic Disorders Therapeutics Market Status by Countries
  - 6.1.1 Europe Metabolic Disorders Therapeutics Sales by Countries (2013-2017)
  - 6.1.2 Europe Metabolic Disorders Therapeutics Revenue by Countries (2013-2017)
  - 6.1.3 Germany Metabolic Disorders Therapeutics Market Status (2013-2017)
  - 6.1.4 UK Metabolic Disorders Therapeutics Market Status (2013-2017)
  - 6.1.5 France Metabolic Disorders Therapeutics Market Status (2013-2017)
  - 6.1.6 Italy Metabolic Disorders Therapeutics Market Status (2013-2017)
  - 6.1.7 Russia Metabolic Disorders Therapeutics Market Status (2013-2017)
  - 6.1.8 Spain Metabolic Disorders Therapeutics Market Status (2013-2017)
  - 6.1.9 Benelux Metabolic Disorders Therapeutics Market Status (2013-2017)
- 6.2 Europe Metabolic Disorders Therapeutics Market Status by Manufacturers
- 6.3 Europe Metabolic Disorders Therapeutics Market Status by Type (2013-2017)

- 6.3.1 Europe Metabolic Disorders Therapeutics Sales by Type (2013-2017)
- 6.3.2 Europe Metabolic Disorders Therapeutics Revenue by Type (2013-2017)
- 6.4 Europe Metabolic Disorders Therapeutics Market Status by Downstream Industry (2013-2017)

## **CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 7.1 Asia Pacific Metabolic Disorders Therapeutics Market Status by Countries
  - 7.1.1 Asia Pacific Metabolic Disorders Therapeutics Sales by Countries (2013-2017)
  - 7.1.2 Asia Pacific Metabolic Disorders Therapeutics Revenue by Countries (2013-2017)
  - 7.1.3 China Metabolic Disorders Therapeutics Market Status (2013-2017)
  - 7.1.4 Japan Metabolic Disorders Therapeutics Market Status (2013-2017)
  - 7.1.5 India Metabolic Disorders Therapeutics Market Status (2013-2017)
  - 7.1.6 Southeast Asia Metabolic Disorders Therapeutics Market Status (2013-2017)
  - 7.1.7 Australia Metabolic Disorders Therapeutics Market Status (2013-2017)
- 7.2 Asia Pacific Metabolic Disorders Therapeutics Market Status by Manufacturers
- 7.3 Asia Pacific Metabolic Disorders Therapeutics Market Status by Type (2013-2017)
  - 7.3.1 Asia Pacific Metabolic Disorders Therapeutics Sales by Type (2013-2017)
  - 7.3.2 Asia Pacific Metabolic Disorders Therapeutics Revenue by Type (2013-2017)
- 7.4 Asia Pacific Metabolic Disorders Therapeutics Market Status by Downstream Industry (2013-2017)

## **CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 8.1 Latin America Metabolic Disorders Therapeutics Market Status by Countries
  - 8.1.1 Latin America Metabolic Disorders Therapeutics Sales by Countries (2013-2017)
  - 8.1.2 Latin America Metabolic Disorders Therapeutics Revenue by Countries (2013-2017)
  - 8.1.3 Brazil Metabolic Disorders Therapeutics Market Status (2013-2017)
  - 8.1.4 Argentina Metabolic Disorders Therapeutics Market Status (2013-2017)
  - 8.1.5 Colombia Metabolic Disorders Therapeutics Market Status (2013-2017)
- 8.2 Latin America Metabolic Disorders Therapeutics Market Status by Manufacturers
- 8.3 Latin America Metabolic Disorders Therapeutics Market Status by Type (2013-2017)
  - 8.3.1 Latin America Metabolic Disorders Therapeutics Sales by Type (2013-2017)
  - 8.3.2 Latin America Metabolic Disorders Therapeutics Revenue by Type (2013-2017)
- 8.4 Latin America Metabolic Disorders Therapeutics Market Status by Downstream

Industry (2013-2017)

## **CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

9.1 Middle East and Africa Metabolic Disorders Therapeutics Market Status by Countries

9.1.1 Middle East and Africa Metabolic Disorders Therapeutics Sales by Countries (2013-2017)

9.1.2 Middle East and Africa Metabolic Disorders Therapeutics Revenue by Countries (2013-2017)

9.1.3 Middle East Metabolic Disorders Therapeutics Market Status (2013-2017)

9.1.4 Africa Metabolic Disorders Therapeutics Market Status (2013-2017)

9.2 Middle East and Africa Metabolic Disorders Therapeutics Market Status by Manufacturers

9.3 Middle East and Africa Metabolic Disorders Therapeutics Market Status by Type (2013-2017)

9.3.1 Middle East and Africa Metabolic Disorders Therapeutics Sales by Type (2013-2017)

9.3.2 Middle East and Africa Metabolic Disorders Therapeutics Revenue by Type (2013-2017)

9.4 Middle East and Africa Metabolic Disorders Therapeutics Market Status by Downstream Industry (2013-2017)

## **CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF METABOLIC DISORDERS THERAPEUTICS**

10.1 Global Economy Situation and Trend Overview

10.2 Metabolic Disorders Therapeutics Downstream Industry Situation and Trend Overview

## **CHAPTER 11 METABOLIC DISORDERS THERAPEUTICS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS**

11.1 Production Volume of Metabolic Disorders Therapeutics by Major Manufacturers

11.2 Production Value of Metabolic Disorders Therapeutics by Major Manufacturers

11.3 Basic Information of Metabolic Disorders Therapeutics by Major Manufacturers

11.3.1 Headquarters Location and Established Time of Metabolic Disorders Therapeutics Major Manufacturer

11.3.2 Employees and Revenue Level of Metabolic Disorders Therapeutics Major Manufacturer

11.4 Market Competition News and Trend

11.4.1 Merger, Consolidation or Acquisition News

11.4.2 Investment or Disinvestment News

11.4.3 New Product Development and Launch

## **CHAPTER 12 METABOLIC DISORDERS THERAPEUTICS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

12.1 Novo Nordisk

12.1.1 Company profile

12.1.2 Representative Metabolic Disorders Therapeutics Product

12.1.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Novo Nordisk

12.2 Sanofi

12.2.1 Company profile

12.2.2 Representative Metabolic Disorders Therapeutics Product

12.2.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Sanofi

12.3 Merck

12.3.1 Company profile

12.3.2 Representative Metabolic Disorders Therapeutics Product

12.3.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Merck

12.4 AstraZeneca

12.4.1 Company profile

12.4.2 Representative Metabolic Disorders Therapeutics Product

12.4.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of AstraZeneca

12.5 Eli Lilly

12.5.1 Company profile

12.5.2 Representative Metabolic Disorders Therapeutics Product

12.5.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Eli Lilly

12.6 AbbVie

12.6.1 Company profile

12.6.2 Representative Metabolic Disorders Therapeutics Product

12.6.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of



## AbbVie

### 12.7 Actelion Pharmaceuticals

#### 12.7.1 Company profile

#### 12.7.2 Representative Metabolic Disorders Therapeutics Product

#### 12.7.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Actelion Pharmaceuticals

### 12.8 Adocia

#### 12.8.1 Company profile

#### 12.8.2 Representative Metabolic Disorders Therapeutics Product

#### 12.8.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Adocia

### 12.9 Aegerion Pharmaceuticals

#### 12.9.1 Company profile

#### 12.9.2 Representative Metabolic Disorders Therapeutics Product

#### 12.9.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Aegerion Pharmaceuticals

### 12.10 Akros Pharma

#### 12.10.1 Company profile

#### 12.10.2 Representative Metabolic Disorders Therapeutics Product

#### 12.10.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Akros Pharma

### 12.11 Alnylam Pharmaceuticals

#### 12.11.1 Company profile

#### 12.11.2 Representative Metabolic Disorders Therapeutics Product

#### 12.11.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals

### 12.12 Amarin

#### 12.12.1 Company profile

#### 12.12.2 Representative Metabolic Disorders Therapeutics Product

#### 12.12.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Amarin

### 12.13 Amicus Therapeutics

#### 12.13.1 Company profile

#### 12.13.2 Representative Metabolic Disorders Therapeutics Product

#### 12.13.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Amicus Therapeutics

### 12.14 Biopharma

#### 12.14.1 Company profile

#### 12.14.2 Representative Metabolic Disorders Therapeutics Product

12.14.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Biopharma

12.15 Arena Pharmaceuticals

12.15.1 Company profile

12.15.2 Representative Metabolic Disorders Therapeutics Product

12.15.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals

12.16 Astellas Pharma

12.17 Bionaturis

12.18 Diasome Pharmaceuticals

12.19 Lexicon Pharmaceuticals

12.20 Ligand Pharmaceuticals

## **CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF METABOLIC DISORDERS THERAPEUTICS**

13.1 Industry Chain of Metabolic Disorders Therapeutics

13.2 Upstream Market and Representative Companies Analysis

13.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF METABOLIC DISORDERS THERAPEUTICS**

14.1 Cost Structure Analysis of Metabolic Disorders Therapeutics

14.2 Raw Materials Cost Analysis of Metabolic Disorders Therapeutics

14.3 Labor Cost Analysis of Metabolic Disorders Therapeutics

14.4 Manufacturing Expenses Analysis of Metabolic Disorders Therapeutics

## **CHAPTER 15 REPORT CONCLUSION**

## **CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE**

16.1 Methodology/Research Approach

16.1.1 Research Programs/Design

16.1.2 Market Size Estimation

16.1.3 Market Breakdown and Data Triangulation

16.2 Data Source

16.2.1 Secondary Sources

16.2.2 Primary Sources

## 16.3 Reference

## I would like to order

Product name: Metabolic Disorders Therapeutics-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

Product link: <https://marketpublishers.com/r/ME85C681305EN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ME85C681305EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

